Hospital
Bedford Memorial Hospital
Bedford Memorial Hospital was paid $14.69M by Medicaid between Jan 2018 and Dec 2024, across 165 billing codes. Its largest line is 99283, emergency room visit (moderate) — 19% of everything it billed.
33Billing provider infoBEDFORD MEMORIAL HOSPITAL
BEDFORD, VA 24523
BEDFORD, VA 24523
33aNPI1295728491assigned 08/24/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$14.69M
24GClaims329,393
24DCodes billed165
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Virginia
Rank by total paid#41 of 80
Median peer was paid$14.69M
This provider vs. median1.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 27,856 | $856K | |
| 2019 | 46,576 | $1.61M | |
| 2020 | 38,884 | $1.64M | |
| 2021 | 48,306 | $1.99M | |
| 2022 | 57,392 | $2.66M | |
| 2023 | 62,849 | $3.15M | |
| 2024incomplete | 47,530 | $2.77M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 19% | 17,666 | 15,736 | $2.82M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 19% | 17,147 | 14,533 | $2.78M |
| 96361 | Intravenous infusion, hydration; each additional hour | 18% | 8,905 | 6,988 | $2.65M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 15% | 13,833 | 11,858 | $2.27M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 5.5% | 3,442 | 3,107 | $809K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 3.2% | 7,936 | 7,299 | $469K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.7% | 2,667 | 2,343 | $402K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.7% | 2,682 | 2,465 | $399K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.8% | 1,232 | 1,117 | $266K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.7% | 2,130 | 1,890 | $247K |
| G0378 | Hospital observation service, per hour | 1.1% | 967 | 829 | $160K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.0% | 2,539 | 1,947 | $153K |
153 more codes
| 80053 | Comprehensive metabolic panel | 1.0% | 18,261 | $147K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 433 | $114K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 2,524 | $98K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 339 | $91K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,623 | $89K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 802 | $76K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 731 | $63K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 463 | $53K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 688 | $35K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 6,526 | $35K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 314 | $32K |
| Q9957 | Injection, perflutren lipid microspheres, per ml | <1% | 604 | $25K |
| 76830 | Ultrasound, transvaginal | <1% | 281 | $24K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 3,562 | $24K |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 4,844 | $23K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,037 | $21K |
| 71250 | <1% | 352 | $20K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 663 | $19K |
| 93971 | <1% | 170 | $16K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 622 | $16K |
| 83880 | <1% | 1,906 | $14K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 6,199 | $13K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 803 | $13K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 190 | $12K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,180 | $12K |
| 80320 | <1% | 1,233 | $9K | |
| 87040 | <1% | 1,632 | $9K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,194 | $8K |
| 81001 | <1% | 15,011 | $7K | |
| 90715 | <1% | 452 | $7K | |
| 84484 | <1% | 7,169 | $7K | |
| 93246 | <1% | 158 | $6K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 926 | $6K |
| 71045 | Radiologic examination, chest; single view | <1% | 2,388 | $6K |
| 80329 | <1% | 543 | $5K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 7,378 | $5K |
| 82962 | <1% | 4,787 | $5K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 10,218 | $5K |
| 85380 | <1% | 1,206 | $5K | |
| 93000 | <1% | 2,839 | $5K | |
| 70496 | <1% | 14 | $5K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 16,141 | $4K |
| J3490 | Unclassified drugs | <1% | 3,053 | $4K |
| 85027 | <1% | 5,667 | $4K | |
| 86900 | <1% | 170 | $3K | |
| 87081 | <1% | 3,616 | $3K | |
| 73630 | <1% | 476 | $3K | |
| 80047 | <1% | 687 | $3K | |
| 72100 | <1% | 218 | $3K | |
| 73610 | <1% | 366 | $2K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 3,975 | $2K |
| 83605 | <1% | 2,949 | $2K | |
| 94060 | <1% | 28 | $2K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 4,887 | $2K |
| 81025 | <1% | 1,076 | $2K | |
| 93976 | <1% | 40 | $2K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 7,392 | $2K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 7,860 | $2K |
| 76801 | <1% | 80 | $2K | |
| 74018 | <1% | 113 | $2K | |
| 82565 | <1% | 682 | $1K | |
| 94729 | <1% | 40 | $1K | |
| 94726 | <1% | 40 | $1K | |
| 96376 | <1% | 2,466 | $1K | |
| 71271 | <1% | 13 | $1K | |
| 84702 | <1% | 816 | $1K | |
| 73030 | <1% | 133 | $1K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,553 | $1K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,033 | $895.90 |
| Q3014 | Telehealth originating site facility fee | <1% | 212 | $891.02 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 7,340 | $747.43 |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 3,375 | $681.94 |
| 94664 | <1% | 385 | $660.07 | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 4,680 | $611.57 |
| 85610 | <1% | 2,890 | $597.47 | |
| 83690 | <1% | 6,788 | $585.49 | |
| 85014 | <1% | 798 | $583.92 | |
| 73564 | <1% | 117 | $502.24 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 952 | $467.78 |
| 73130 | <1% | 178 | $419.25 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,608 | $407.52 |
| 87210 | <1% | 979 | $382.45 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 597 | $371.49 |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 28 | $356.04 |
| 73110 | <1% | 60 | $354.26 | |
| 81003 | <1% | 407 | $348.38 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 6,433 | $325.83 |
| 29125 | <1% | 16 | $314.56 | |
| 70498 | <1% | 15 | $253.17 | |
| 83735 | <1% | 2,600 | $250.39 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 1,105 | $214.53 |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 137 | $197.66 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 3,081 | $192.66 |
| 0296T | <1% | 12 | $188.43 | |
| 82803 | <1% | 577 | $175.25 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 2,360 | $157.87 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 2,274 | $154.06 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,859 | $136.80 |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 28 | $123.25 |
| 73562 | <1% | 17 | $94.76 | |
| 87186 | <1% | 1,218 | $89.16 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 5,203 | $86.56 |
| 73140 | <1% | 12 | $69.76 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 861 | $67.93 |
| 87147 | <1% | 642 | $66.91 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,243 | $61.26 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,160 | $59.73 |
| 87807 | <1% | 140 | $52.20 | |
| 80061 | Lipid panel | <1% | 16 | $49.45 |
| 87077 | <1% | 241 | $31.48 | |
| 84703 | <1% | 182 | $23.50 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 672 | $19.77 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 365 | $16.27 |
| 84145 | <1% | 28 | $15.36 | |
| 86140 | <1% | 154 | $12.62 | |
| 87088 | <1% | 364 | $12.24 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 62 | $11.32 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 158 | $10.65 |
| 84100 | <1% | 138 | $10.64 | |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 60 | $10.64 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 134 | $7.91 |
| J2704 | Injection, propofol, 10 mg | <1% | 1,063 | $7.67 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 51 | $5.83 |
| 82947 | <1% | 13 | $5.32 | |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 13 | $4.77 |
| J1815 | Injection, insulin, per 5 units | <1% | 92 | $4.72 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 49 | $4.41 |
| 80143 | <1% | 32 | $3.79 | |
| 86901 | <1% | 170 | $3.34 | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 56 | $2.31 |
| 80179 | <1% | 31 | $1.90 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 38 | $0.98 |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | <1% | 17 | $0.92 |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 189 | $0.72 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 140 | $0.24 |
| Q0144 | Azithromycin dihydrate, oral, capsules/powder, 1 gram | 0% | 36 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 38 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 17 | $0.00 |
| A4216 | Sterile water, saline and/or dextrose, diluent/flush, 10 ml | 0% | 1,188 | $0.00 |
| J1644 | Injection, heparin sodium, per 1000 units | 0% | 34 | $0.00 |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 0% | 13 | $0.00 |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 13 | $0.00 |
| 85730 | 0% | 53 | $0.00 | |
| 94760 | 0% | 254 | $0.00 | |
| 99070 | 0% | 582 | $0.00 | |
| 85652 | 0% | 17 | $0.00 | |
| 86850 | 0% | 31 | $0.00 | |
| 82550 | 0% | 50 | $0.00 | |
| 87184 | 0% | 53 | $0.00 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 16 | $0.00 |
| J3480 | Injection, potassium chloride, per 2 meq | 0% | 22 | $0.00 |
| 94761 | 0% | 34 | $0.00 | |
| G1011 | Clinical decision support mechanism, qualified tool not otherwise specified, as defined by the medicare appropriate use criteria program | 0% | 46 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialJOHNSON, REBECCA (DIRECTOR, PROFESSIONAL BILLING)
| Provider | Location | Paid |
|---|---|---|
| RMH Emergency Services, LLC | Roanoke, VA | $365K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.